A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.
A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.
Day Two of TAS25 kicks off with a presentation by Professor Madelon Maurice from the Madelon Maurice Lab in Holland.
Peter Senter, Ph.D., Janine Schuurman, Ph.D., and Greg Thurber, Ph.D. — now that’s a lineup.
Peter Senter, Ph.D., is the keynote for TAS25. Peter joined Seattle Genetics in 1998 and was part of the research team focused on anticancer therapies before the company’s $43 billion sale to Pfizer in 2023.
So grateful to the team at FairJourney Biologics for inviting our team to TAS25, their high-science discovery show in Porto, Portugal.
That’s Nice is visiting the FairJourney Biologics facilities in Porto, Portugal, as a kick-off to TAS2025: The Anti-Body Series.
Exciting to be able to check out the expanded construction at IDT’s facility in Germany.
A sneak peek at our first BIO interview: Mr. Mark Womack, CEO of BioCina.
Shoutout to Steve Favaloro of Genezen for being one of our 20 interview subjects at this year’s BIO in Boston.
Andy Fenny and the SK pharmteco team getting ready to board the Spirit of Boston.